IRIS
DELLA CORTE, Carminia Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.360
NA - Nord America 3.454
AS - Asia 3.293
SA - Sud America 403
Continente sconosciuto - Info sul continente non disponibili 281
AF - Africa 44
OC - Oceania 6
Totale 14.841
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 5.185
US - Stati Uniti d'America 3.350
SG - Singapore 1.146
IT - Italia 680
IE - Irlanda 631
HK - Hong Kong 620
CN - Cina 598
VN - Vietnam 389
BR - Brasile 334
DE - Germania 230
KR - Corea 179
GB - Regno Unito 146
FR - Francia 117
IN - India 100
JP - Giappone 75
UA - Ucraina 74
FI - Finlandia 63
CA - Canada 54
NL - Olanda 47
AT - Austria 41
BD - Bangladesh 39
GR - Grecia 35
TR - Turchia 29
MX - Messico 27
SE - Svezia 25
AR - Argentina 23
PK - Pakistan 19
PL - Polonia 19
ID - Indonesia 18
IQ - Iraq 14
EC - Ecuador 13
ES - Italia 12
CL - Cile 11
ZA - Sudafrica 11
BE - Belgio 10
CZ - Repubblica Ceca 10
PH - Filippine 8
PY - Paraguay 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
CO - Colombia 7
SA - Arabia Saudita 7
AZ - Azerbaigian 6
DO - Repubblica Dominicana 6
HU - Ungheria 6
KE - Kenya 6
MA - Marocco 5
TH - Thailandia 5
TN - Tunisia 5
VE - Venezuela 5
JM - Giamaica 4
JO - Giordania 4
KG - Kirghizistan 4
LT - Lituania 4
PT - Portogallo 4
AO - Angola 3
AU - Australia 3
CR - Costa Rica 3
DZ - Algeria 3
IR - Iran 3
NZ - Nuova Zelanda 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
UZ - Uzbekistan 3
AL - Albania 2
AM - Armenia 2
EG - Egitto 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
MY - Malesia 2
PA - Panama 2
PE - Perù 2
SI - Slovenia 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
HN - Honduras 1
IS - Islanda 1
KW - Kuwait 1
LY - Libia 1
NI - Nicaragua 1
NP - Nepal 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TZ - Tanzania 1
Totale 14.560
Salva come PNG Salva come JPEG
Città #
Moscow 1.906
San Jose 629
Dublin 623
Hong Kong 605
Singapore 543
Santa Clara 398
Chandler 285
Ashburn 213
Naples 192
Seoul 178
Jacksonville 139
Council Bluffs 136
Beijing 132
Ho Chi Minh City 132
Dallas 118
New York 94
Hefei 92
Munich 86
Hanoi 83
Los Angeles 75
Princeton 72
Roxbury 70
Bremen 60
The Dalles 59
Bengaluru 55
Medford 36
Turku 36
Cambridge 35
Caserta 35
São Paulo 33
Rome 28
Nuremberg 26
Da Nang 25
Wilmington 24
Vienna 23
Dong Ket 20
Amsterdam 19
Boardman 19
Elora 18
Des Moines 17
Haiphong 17
Milan 17
Napoli 17
Chicago 16
Warsaw 16
Ann Arbor 15
Orem 15
Tokyo 14
Aversa 13
Piscataway 13
London 12
Afragola 11
Atlanta 11
Brooklyn 11
Frankfurt am Main 11
Columbus 10
Falkenstein 10
Florence 10
Phoenix 10
Rio de Janeiro 10
Shanghai 10
Toronto 10
Belo Horizonte 9
Brussels 9
Ercolano 9
Istanbul 9
Biên Hòa 8
Brno 8
Chennai 8
Dhaka 8
Lappeenranta 8
Montreal 8
Mumbai 8
Pozzuoli 8
San Francisco 8
Boston 7
Guangzhou 7
Helsinki 7
Hillsboro 7
Jakarta 7
Madrid 7
Rawalpindi 7
Seattle 7
Baku 6
Brasília 6
Buffalo 6
City of London 6
Houston 6
Hải Dương 6
Mexico City 6
Nanjing 6
Phủ Lý 6
San Mateo 6
Stockholm 6
Venice 6
Viterbo 6
Woodbridge 6
Asunción 5
Bahawalpur 5
Battipaglia 5
Totale 7.911
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 226
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 208
The use of ultrasound in the evaluation of postoperative pneumothorax and lung re-expansion in patients after lung resection 202
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 193
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 189
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 188
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review 187
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 187
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 186
Immunotherapy for head and neck cancer: Present and future 175
Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy 167
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 165
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 164
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 164
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 162
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 161
Prediction of preoperative intrathoracic adhesions for ipsilateral reoperations: sliding lung sign 161
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 160
A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS-The Experience in Pathological Anatomy Unit 160
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 155
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 153
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 152
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 152
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 152
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 152
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 149
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 149
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 149
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 148
Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors 148
Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond 146
AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors 145
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 144
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 143
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 142
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 142
Discovery of N-Substituted-2-Oxoindolin Benzoylhydrazines as c-MET/SMO Modulators in EGFRi-Resistant Non-Small Cell Lung Cancer 140
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 140
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 139
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 138
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs 137
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 136
Ventilation challenge in rigid bronchoscopy: Laser tube as an alternative management in patients with lung cancer and central airway obstruction 136
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 134
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 134
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 133
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 132
Diagnosis of malignant pleural disease: Ultrasound as "a detective probe" 132
Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report. 130
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 130
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era 130
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 126
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 126
Translational insights and new therapeutic perspectives in head and neck tumors 126
Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study 124
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 124
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 124
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 122
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 122
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 121
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 120
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 120
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 119
Rescue Surgery for Advanced Stage Lung Cancer: A Systematic Review 118
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 117
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy 116
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems 115
Application of Telepathology for Rapid On-Site Evaluation of Touch Imprint Cytology in CT-Guided Percutaneous Transthoracic Core Needle Biopsy of Pulmonary Nodules: The Experience of Our Multidisciplinary Thoracic Tumor Board 115
Urtica dioica L. inhibits proliferation and enhances cisplatin cytotoxicity in NSCLC cells via Endoplasmic Reticulum-stress mediated apoptosis 114
Primary pleural squamous cell carcinoma: A diagnostic challenge 113
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 112
Hypothalamic–pituitary autoimmunity in patients treated with anti-pd-1 and anti-pd-l1 antibodies 112
Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma 112
Functional effect of adiponectin and body composition assessment in lung cancer subjects after video-assisted thoracoscopic surgery (VATS) lobectomy 112
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 111
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 110
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 109
PATZ1 in Non-Small Cell Lung Cancer: A New Biomarker That Negatively Correlates with PD-L1 Expression and Suppresses the Malignant Phenotype 108
Mechanisms of resistance to EGFR-targeted drugs: lung cancer 108
Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy 107
Unleashing precision: A review of targeted approaches in pleural mesothelioma 107
Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer 106
Kisspeptin and cancer: Molecular interaction, biological functions, and future perspectives 106
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC 105
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines 104
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 103
ROLE OF THE HEDGEHOG PATHWAY IN MEDIATING RESISTANCE TO ANTI-EGFR TYROSINE KINASE INHIBITORS IN NON SMALL CELL LUNG CANCER 102
Implication of the Hedgehog pathway in hepatocellular carcinoma. 102
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 102
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study 99
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. 99
Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy? 97
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 96
ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer 96
The role of coronary artery calcification score in lung cancer patients 96
Role of Cardiac Biomarkers in Non-Small Cell Lung Cancer Patients 96
Evading the STING: LKB1 loss leads to STING silencing and immune escape in KRAS-mutant lung cancers 94
Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR 93
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities 93
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype 92
Totale 13.318
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.487
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.487
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022492 0 7 9 9 110 10 44 18 26 37 67 155
2022/20231.193 114 30 25 114 127 92 12 58 558 13 29 21
2023/2024612 61 25 24 30 170 80 20 24 11 17 53 97
2024/20252.183 26 51 22 56 307 277 267 199 333 318 166 161
2025/20269.264 396 455 439 360 774 4.817 612 492 367 269 170 113
2026/2027396 155 241 0 0 0 0 0 0 0 0 0 0
Totale 14.841